ProCE Banner Activity

Evolving Options for First-line ART and Switch Strategies

Slideset Download
Expert-authored slides on selecting among current guideline-recommended initial ART regimens, identifying appropriate switch strategies for patients with virologic suppression on 3-drug ART, including 2-drug oral therapy and long-acting 2-drug injectable therapy options, and new data on effective management of virologic breakthrough with NNRTI-based regimens.

Released: September 09, 2021

Expiration: September 08, 2022

Share

Faculty

Rajesh Gandhi

Rajesh Gandhi, MD

Assistant Professor of Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Merck Sharp & Dohme Corp.

ViiV Healthcare

Program Director Disclosure

Program Director

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare and funds for research support from Janssen.

Faculty Disclosure

Primary Author

Rajesh Gandhi, MD

Assistant Professor of Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts

Rajesh T. Gandhi, MD, has disclosed that he has received consulting fees from Merck.